Showing results (111-120 of 379) with videos related to
Sort By:
Pageof 38
Expert Opinion on Drug Safety|October 21, 2017
The safety and efficacy of dabrafenib and trametinib for the treatment of melanomaSarah Knispel, Lisa Zimmer, Theodora Kanaki, et al.Scientific Reports|July 7, 2019
Macroangiopathy is a positive predictive factor for response to immunotherapyKaterina Deike-Hofmann, Lukas Gutzweiler, Julia Reuter, et al.Cancers|October 21, 2020
Arthralgia Induced by BRAF Inhibitor Therapy in Melanoma PatientsMartin Salzmann, Karolina Benesova, Kristina Buder-Bakhaya, et al.Journal for Immunotherapy of Cancer|November 15, 2019
Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center studyMarkus V Heppt, Teresa Amaral, Katharina C Kähler, et al.Deutsches Arzteblatt International|April 4, 2019
Checkpoint InhibitorsLucie Heinzerling, Enrico N de Toni, Georg Schett, et al.Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 4, 2009
Quality of medical care of patients with acne vulgaris in Germany--nationwide survey of pharmacy clientsNadine Franzke, Lisa Zimmer, Ines Schäfer, et al.Life (Basel, Switzerland)|April 3, 2021
Expression of Potential Targets for Cell-Based Therapies on Melanoma CellsSophia B Strobel, Devayani Machiraju, Ingrid Hülsmeyer, et al.Lancet (London, England)|May 18, 2020
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trialLisa Zimmer, Elisabeth Livingstone, Jessica C Hassel, et al.European Journal of Cancer (Oxford, England : 1990)|March 14, 2024
Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanomaLea Jessica Albrecht, Florentia Dimitriou, Piyush Grover, et al.Oncoimmunology|June 9, 2021
Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patientsDevayani Machiraju, Melanie Wiecken, Nina Lang, et al.Pageof 38